Brief: Cytodyn Says Patient With Covid-19 Exhibited Clinical Improvement After Treatment With Co's Investigational New Drug, Leronlimab
09/04/2020 11:36
April 9 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN - ANNOUNCED TODAY PATIENT WITH COVID-19 EXHIBITED
CLINICAL IMPROVEMENT AFTER TREATMENT WITH CO'S INVESTIGATIONAL
NEW DRUG, LERONLIMAB
* CYTODYN INC - HAS INITIATED ENROLLMENT IN A PHASE 2
RANDOMIZED
CLINICAL TRIAL FOR MILD-TO-MODERATE COVID-19 POPULATION IN U.S.
* CYTODYN INC - ENROLLING IN A PHASE 2B/3 RANDOMIZED
CLINICAL
TRIAL FOR SEVERE AND CRITICALLY ILL COVID-19 POPULATION
Source text for Eikon: ID:nGNX3g8c0G
Further company coverage: CYDY.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer